- In January 2024, The U.S. FDA granted marketing approval for Lupin’s Dapagliflozin and Saxagliptin tablets, a generic version of AstraZeneca’s Qtern tablets. This approval marks a significant step in providing affordable treatment options for Type 2 Diabetes, combining two medications that work together to regulate blood sugar levels in diabetic patients
- In January 2024, Glenmark Pharmaceuticals Ltd. launched Lirafit, a biosimilar of Liraglutide, in India. Lirafit is designed for Type 2 diabetes management and offers a cost-effective alternative to the brand-name drug. At a price of USD 1.21 per day for a 1.2 mg dose, it aims to improve accessibility to diabetes care in India
- In December 2023, The Union Minister launched the Rural Diabetes Prevention & Control Campaign in Varanasi, India. The initiative aims to raise awareness about Type 2 Diabetes Mellitus in rural areas. By educating the population on prevention, early detection, and management of diabetes, this campaign seeks to combat the rising prevalence of the disease
- In May 2023, Eli Lilly and Company launched a consumer campaign to introduce Mounjaro, a new Type 2 diabetes drug. Mounjaro utilizes a unique mechanism of action and offers a novel approach to blood sugar control. The campaign focuses on informing the public about the drug’s benefits in improving diabetes management
- In December 2022, Glenmark Pharmaceuticals Ltd. launched Zita-PioMet, a triple fixed-dose combination (FDC) drug for Type 2 diabetes treatment in India. The combination of Teneligliptin, Pioglitazone, and Metformin offers patients a convenient and effective solution for managing blood glucose levels. This drug enhances the accessibility of comprehensive diabetes care in India
- In September 2022, Novo Nordisk A/S introduced an unbranded biologic version of Tresiba (insulin degludec) injection, a long-acting basal insulin, for diabetes management. Indicated for patients aged one year and older, Tresiba helps regulate blood sugar levels. Its unbranded version makes diabetes treatment more affordable and accessible for patients worldwide
- In August 2022, Cadila Pharmaceuticals launched generic versions of Sitagliptin in India under the brand names Jankey and Sitenali. These generic medications target Type 2 diabetes and provide a more affordable alternative to the original Sitagliptin. The introduction of these drugs aims to address the increasing demand for diabetes treatments in the Indian market
